Contributions in the domain of cancer research: Review human papillomaviruses and their role in cervical cancer

Cellular and Molecular Life Sciences

Volumn 58, Issue 12-13, 2001, Pages 1923-1942

  Dell, G ^a   Gaston, K ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cervical cancer; Early protein; Gene expression; p53; Papillomavirus; Rb; Tumour suppressor protein; Viral oncogene

Indexed keywords

DNA BINDING PROTEIN; FLUOROURACIL; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; VIRUS PROTEIN; VIRUS VACCINE; E1 PROTEIN, HUMAN PAPILLOMAVIRUS 16; ONCOGENE PROTEIN E2, HUMAN PAPILLOMA VIRUS TYPE 16; ONCOGENE PROTEIN E6, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7 HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7-HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN P53;

CARCINOGENESIS; HUMAN; REVIEW; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS CLASSIFICATION; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; PAPOVAVIRIDAE; VERRUCA; VERRUCA VULGARIS VIRUS;

CELL CYCLE; CERVIX NEOPLASMS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMAN; MODELS, MOLECULAR; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS, HUMAN; PROTEIN P53; PROTEIN STRUCTURE, TERTIARY; SUPPORT, NON-U.S. GOV'T; TUMOR VIRUS INFECTIONS;

EID: 0035193540     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000827     Document Type: Review

References (255)

1. Viruses in human tumours - Reminiscences and perspectives
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
3. Epidemiology of HPV infection among Mexican women with normal cervical cytology
4. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types
5. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours
6. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
7. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines
8. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm
9. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas
10. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1
11. Sequence variation in the upstream regulatory region of HPV 18 isolates from cervical cancers
12. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells
13. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis
14. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites
15. Recurrent integration of papillomavirus DNA within the human 12q14-15 uterine breakpoint region in genital carcinomas
16. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines
17. The integration of HPV-18 DNA in cervical carcinoma
18. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity
19. Integration of human papillomavirus type 16 DNA sequences: A possible early event in the progression of genital tumors
20. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene
21. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene
22. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis
23. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway
24. Gynecologic malignancies in immunosuppressed organ homograft recipients
25. Human papillomavirus and lower genital neoplasia in renal transplant patients
26. The common occurrence of human papillomavirus infection and intraepithelial neoplasia in women infected by HIV
27. Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus
28. Human immunodeficiency virus-induced immunosuppression: A risk factor for human papillomavirus infection
29. Smoking and cervical cancer - Current status: A review
30. Cigarette smoking and neoplasia of the uterine cervix: Smoke constituents in cervical mucus
31. Effect of cigarette smoking on cervical epithelial immunity: A mechanism for neoplastic change?
32. Local immunity and the uterine cervix: Implications for cancer-associated viruses
33. Risk factors for cervical intraepithelial neoplasia: Differences between low- And high-grade lesions
34. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells
35. Human papillomavirus type 16 expression in cervical keratinocytes: Role of progesterone and glucocorticoid hormones
36. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18
37. Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo
38. Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone
39. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells
40. Morphometric study of intraepithelial neoplasia of the uterine cervix
41. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis
42. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells
43. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis
44. Estrogen metabolism and the malignant potential of human papillomavirus immortalized keratinocytes
45. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes
46. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals
47. Association of human papillomavirus types 16 and 18 E6 proteins with p53
48. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
49. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells
50. 2+-binding fragment from the human papillomavirus type 16 E6 protein
51. Identification of the human papillomavirus type 18 E6 and E6 proteins in nuclear protein fractions from human cervical carcinoma cells grown in the nude mouse or in vitro
52. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome
53. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins
54. Intracellular localization and DNA-binding properties of human papillomavims type 18 E6 protein expressed with a baculovirus vector
55. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions
56. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalise keratinocytes in culture
57. Activation of the c-Fos gene by the HPV16 oncoproteins depends on the cAMP-response element at -60
58. Mutational analysis of transcriptional activation by the bovine papillomavirus type 1 E6
59. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein
60. Recognition and manipulation of branched DNA structure by junction-resolving enzymes
61. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage
62. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
63. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
64. Specific loss of apoptotic but not cell-cycle arrest function in a human tumour derived p53 mutant
65. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells
66. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavims types 16 or 18
67. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53
68. p53 protein is a suppressor of papillomavirus DNA amplificational replication
69. Cell-specific modulation of papovavirus replication by tumor suppressor protein p53
70. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
71. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
72. p53 polymorphism and risk of cervical cancer
73. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism
74. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix
75. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer
76. Human papillomavirus type 16 E6 variants in cervical carcinoma: Relationship to host genetic factors and clinical parameters
77. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis
78. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalisation of mammary epithelial cells
79. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase
80. Recruitment of p300/CBP in p53-dependent signal pathways
81. Synergistic activation of transcription by CBP and p53
82. Binding and modulation of p53 by p300/CBP coactivators
83. The human papillomavims type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional co-activator CBP/p300
84. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300
85. Functional p53 protein in human papillomavirus-positive cancer cells
86. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation
87. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint
88. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle
89. Human scribble (vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase
90. Role of the cytoskeletal protein paxillin in oncogenesis
91. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton
92. Association of bovine papillomavirus type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif
93. Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP
94. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types
95. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms
96. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalisation of human papillomavirus type 16- and 18-transfected human keratinocytes
97. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization
98. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias
99. Differential regulation of human papillomavirus E6 by protein kinase A: Conditional degradation of human discs large protein by oncogenic E6
100. PKN binds and phosphorylates human papillomavirus E6 oncoprotein
101. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A
102. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle
103. The human papilloma virus-16 E7 oncoprotein is able to bind the retinoblastoma gene product
104. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells
105. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
106. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein
107. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II
108. Human papillomavirus 16 E7 protein is associated with the nuclear matrix
109. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation
110. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130
111. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins
112. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein
113. A point mutational analysis of human papillomavirus type 16 E7 protein
114. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells
115. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16
116. Analysis of the conformational change of recombinant human papillomavirus type 18 E7 protein induced by metal binding
117. Predicted α-helix/β-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7
118. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerisation, and transformation but not for Rb binding
119. The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells
120. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes
121. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth
122. The E2F transcription factors: Key regulators of cell proliferation
123. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7
124. p107 and p130: Versatile proteins with interesting pockets
125. The Pezcoller lecture: Cancer cell cycles revisited
126. 1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E
127. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits un-scheduled DNA synthesis reactivated in differentiated keratinocytes
128. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2
129. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype
130. Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumour suppressor protein
131. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis
132. Disruption of retinoblastoma protein family function by human papillomavirus type 16 E7 oncoprotein inhibits lens development in part through E2F-1
133. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16(INK4a)-imposed G(1) cell cycle arrest
134. The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent
135. Repression of p53 transcriptional activity by the HPV E7 proteins
136. Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP
137. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha
138. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α
139. Interferon response depends on viral transcription in human papillomavirus-containing lesions
140. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors
141. Rb binds c-Jun and activates transcription
142. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth
143. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3
144. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein
145. Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein
146. Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA
147. Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines
148. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: Targeting via ubiquitination of the N-terminal residue
149. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle
150. Identification of the E5 open reading frame of human papillomavirus type 16
151. DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein
152. Structural models of the bovine papillomavirus E5 protein
153. Temporal and spatial expression of the E5a protein during the differentiation-dependent life cycle of human papillomavirus type 31b
154. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus
155. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor
156. The HPV16 E5 protein: Expression, detection, and stable complex formation with transmembrane proteins in COS cells
157. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein
158. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes
159. Vacuolar H(+)-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein
160. The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors
161. The transmembrane domain of the E5 oncoprotein contains functionally discrete helical faces
162. Golgi alkalinization by the papillomavirus E5 oncoprotein
163. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix
164. Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains
165. Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: Implications for its DNA binding-site selection mechanism
166. Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: Evidence for flexible DNA-binding regions
167. Structure of the intact transactivation domain of the human papillomavirus E2 protein
168. Crystal structure of the human papillomavirus type 18 E2 transactivation domain
169. DNA binding and bending by the human papillomavirus type 16 E2 protein: Recognition of an extended binding site
170. Crystal structure at 1.75 Å of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target
171. The structural basis of DNA target discrimination by papillomavirus E2 proteins
172. DNA bending is induced in an enhancer by the DNA-binding domain of the bovine papillomavirus E2 protein
173. Conformational changes and stabilization induced by ligand binding in the DNA-binding domain of the E2 protein from human papillomavirus
174. DNA structure and flexibility in the sequence-specific binding of papillomavirus E2 proteins
175. Subunit rearrangement accompanies sequence-specific DNA binding by the bovine papillomavirus-1 E2 protein
176. Evidence for cooperativity between E2 binding sites in E2 transregulation of bovine papillomavirus type 1
177. Cooperative binding of the E2 protein of bovine papillomavirus to adjacent E2-responsive sequences
178. The activation domain of the bovine papillomavirus E2 protein mediates association of DNA-bound dimers to form DNA loops
179. The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex
180. During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element
181. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID
182. Cooperativity in vivo between the E2 transactivator and the TATA box binding protein depends on core promoter structure
183. Trans-activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: Cooperation with activation domains of cellular transcription factors
184. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein
185. Characterization of the human papillomavirus E2 protein: Evidence of trans-activation and trans-repression in cervical keratinocytes
186. Kinetic and equilibrium binding studies of the human papillomavirus type-16 transcription regulatory protein E2 interacting with core enhancer elements
187. A fluorescence anisotropy study of DNA binding by HPV-11 E2C protein: A hierarchy of E2-binding sites
188. Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB
189. The bovine papillomavirus 1 E2 protein contains two activation domains: One that interacts with TBP and another that functions after TBP binding
190. Conserved interaction of the human papillomavirus E2 transcriptional activator proteins with human and yeast TFIIB proteins
191. Functional interaction of the bovine papillomavirus E2 transactivation domain with TFIIB
192. Functional interaction of a novel cellular protein with the papillomavirus E2 transactivation domain
193. Mechanism of action of the papillomavirus E2 repressor: Repression in the absence of DNA binding
194. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line
195. The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes
196. The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31
197. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells
198. Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition
199. Suppression of cellular proliferation by the papillomavirus E2 protein
200. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines
201. Interaction between the HPV-16 E2 transcriptional activator and p53
202. cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription
203. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development
204. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells
205. p53 mediated apoptosis in HeLa cells: Transcription dependent and independent mechanisms
206. Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53
207. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins
208. Transient replication of human papillomavirus DNAs
209. Structure and function of hexameric helicases
210. Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein
211. Biochemical and electron microscopic analysis of the hexameric E1 helicase
212. Characterisation of the DNA-binding domain of the bovine papillomavirus replication initiator E1
213. Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin
214. A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit
215. Crystal structure of the DNA binding domain of the replication initiation protein E1 from papillomavirus
216. Bovine papillomavirus type 1 E1 replication-defective mutants are altered in their transcriptional regulation
217. Repression of bovine papillomavirus type 1 transcription by the E1 replication protein
218. The bovine papillomavirus type 1 (BPV1) replication protein E1 modulates transcriptional activation by interacting with BPV1 E2
219. The bovine papillomavirus E2 transactivator is stimulated by the E1 initiator through the E2 activation domain
220. Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin
221. Functional interactions between papillomavirus E1 and E2 proteins
222. Induction of structural changes in the bovine papillomavirus type 1 origin of replication by the viral E1 and E2 proteins
223. Formation of the complex of bovine papillomavirus E1 and E2 proteins is modulated by E2 phosphorylation and depends upon sequences within the carboxyl terminus of E1
224. Recruitment and loading of the E1 initiator protein: An ATP-dependent process catalyzed by a transcription factor
225. The bovine papillomavirus E2 protein modulates the assembly of but is not stably maintained in a replication-competent multimeric E1-replication origin complex
226. Subunit affinities and stoichiometries of the human papillomavirus type 11 E1:E2:DNA complex
227. The cellular DNA polymerase alpha-primase is required for papillomavirus DNA replication and associates with the viral E1 helicase
228. Human papillomavirus DNA replication: Interactions between the viral E1 protein and two subunits of human DNA polymerase alpha/primase
229. Identification of domains of the HPV11 E1 protein required for DNA replication in vitro
230. The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication
231. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle
232. C is and trans requirements for stable episomal maintenance of the BPV-1 replicator
233. Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin
234. Magnesium ions enhance the transfer of human papillomavirus E2 protein from non-specific to specific binding sites
235. Improved treatment for cervical cancer - Concurrent chemotherapy and radiotherapy
236. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
237. Therapeutic approaches to genital warts
238. Cervical cancer vaccines: Emerging concepts and developments
239. Papillomaviruses: Prophylactic vaccine prospects
240. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
241. A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro
242. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18E6
243. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein
244. Potential drugs against cervical cancer: Zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein
245. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA
246. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells
247. Activation of p53 in cervical carcinoma cells by small molecules
248. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein
249. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia
250. Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus
251. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity